TIA
LUCD icon

Traphagen Investment Advisors’s Lucid Diagnostics LUCD Stock Holding History

Traphagen Investment Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.7K Buy
58,590
+29,295
+100% +$31.6K ﹤0.01% 216
2026
Q1 		$33.7K Hold
29,295
– – ﹤0.01% 203
2025
Q4 		$31.9K Hold
29,295
– – ﹤0.01% 193
2025
Q3 		$29.6K Hold
29,295
– – ﹤0.01% 190
2025
Q2 		$33.7K Buy
+29,295
New +$37.8K ﹤0.01% 185

Other funds holding LUCD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return
PCM
Perkins Capital Management Wayzata, Minnesota $133M AUM 127.86% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
XF
XML Financial Bethesda, Maryland $1.37B AUM 28.49% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Traphagen Investment Advisors's LUCD Position: Q2 2026 in Review

Traphagen Investment Advisors increased its Lucid Diagnostics (LUCD) stake by 100% in Q2 2026, buying an estimated $31.6K and bringing the position to 58,590 shares worth $62.7K. The position accounts for ﹤0.01% of the portfolio, ranked #216.

Traphagen Investment Advisors first reported a position in LUCD in Q2 2025 and has held it in 5 quarters since. 48 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Traphagen Investment Advisors held 58,590 shares of Lucid Diagnostics worth $62.7K as of Q2 2026.
  • Traphagen Investment Advisors bought 29,295 Lucid Diagnostics shares in Q2 2026, an estimated $31.6K.
  • Lucid Diagnostics made up ﹤0.01% of Traphagen Investment Advisors's portfolio in Q2 2026, its #216 holding.
  • Traphagen Investment Advisors first reported a position in Lucid Diagnostics in Q2 2025 and has held it in 5 quarters since.
  • 48 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Traphagen Investment Advisors's 13F filing for Q2 2026, filed 16 Jul 2026.